Catalio Capital Management
Investment Details
Investor Type
Venture Capital
Asset Class Focus
Private Equity, Venture Capital
Stage Focus
Seed, Early Stage, Series A, Series B, Growth, Late Stage, Pre-IPO, Buyout, Turnaround, Distressed
Geographical Focus
United States, United Kingdom, Canada, Germany, Hong Kong, Japan, Australia, Singapore, China, India, Brazil, France, United Arab Emirates, Switzerland, Mexico, South Korea, South Africa, Israel, Taiwan
Industries Focus
- Healthcare
- Life Sciences
- Pharmaceuticals
- Medical Devices
- Diagnostics
- Biotechnology
- Regenerative Medicine
- Oncology
- Neurology
- Cardiology
- Immunology
- Genomics
- Medical Technology
- Healthcare IT
- Orthopedics
Investment Size:
10,000,000 to 50,000,000 USD
Investor Details Founded: 2020
Catalio Capital Management is a New York-based venture capital firm specializing in healthcare and biotechnology investments. Founded in 2020 by George C. Petrocheilos and Dr. R. Jacob Vogelstein, the firm focuses on breakthrough biomedical technologies across private equity and venture capital stages. Catalio has raised over $400 million for its fourth fund, Catalio Nexus Fund IV, which has already invested in 16 companies, including PinkDx and Superluminal Medicines. The firm operates globally with offices in New York, Washington D.C., and London, and collaborates with a network of over 45 venture partners, including Nobel Prize winners and serial scientist-entrepreneurs. Catalio's investment strategy centers on identifying and supporting transformative biomedical companies at all stages, leveraging its scientific expertise and extensive advisor network to evaluate and back companies deeply. The firm has completed more than 20 exits since its founding, including ArriVent BioPharma, Recursion Pharmaceuticals, Thrive Earlier Detection, and Haystack Oncology.
Requirements
- Focus on healthcare and biotechnology sectors
- Preference for companies with innovative biomedical technologies
- Interest in both private equity and venture capital stages
- Global operational scope with offices in New York, Washington D.C., and London
- Collaboration with a network of over 45 venture partners, including Nobel Prize winners and serial scientist-entrepreneurs
- Investment strategy centers on identifying and supporting transformative biomedical companies at all stages
- Leverages scientific expertise and extensive advisor network to evaluate and back companies deeply
- Completed more than 20 exits since its founding, including ArriVent BioPharma, Recursion Pharmaceuticals, Thrive Earlier Detection, and Haystack Oncology
Contact
[Official Website Hidden]
[LinkedIn Profile Hidden]
[HQ Location Hidden]
[Email Hidden]
[Contact Number Hidden]
Portfolio Companies
- PinkDx
- Superluminal Medicines
- Rhapsogen
- TBD Pharma
- Protara Therapeutics
- Imperative Care
- Alentis Therapeutics
- ArriVent BioPharma
- Recursion Pharmaceuticals
- Thrive Earlier Detection
- Haystack Oncology
Mentioned In
-
$49.95
-
$9.95
-
$14.95
-
$39.95
-
$24.95
-
$19.95
-
$19.95
-
$24.95
-
$99.00
-
$299.00
-
$95.00
Claim this Investor
Are you an official representative of Catalio Capital Management?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim